Therapeutic Options For Pseudomonas aeruginosa: A Pharmacological Review

Emergence of Pseudomonas aeruginosa : The historical evolution of Pseudomonas aeruginosa reflects the progressive understanding of a pathogen that has become a major therapeutic concern in modern medicine.The earliest clinical recognition dates back to 1850, when Sédillot observed the characteristic blue-green discoloration of surgical wound dressings, suggesting its association with human infection.In 1860, Fordos isolated the blue pigment, later identified as pyocyanin, and in 1862, Lücke correlated this pigment with rod-shaped bacteria.A significant milestone occurred in 1882 when Carle Gessard achieved the first pure culture isolation from bluish-green wound pus.Between 1889 and 1894, the organism was firmly established as the etiological agent of blue-green purulent wound infections, and in 1894, Walter Migula formally designated the genus Pseudomonas.By 1916, its mechanisms of invasion and dissemination were further elucidated.With the advent and widespread use of antimicrobial agents, P. aeruginosa emerged as a quintessential opportunistic nosocomial pathogen, notable for its intrinsic and acquired resistance mechanisms, which now pose substantial pharmacotherapeutic challenges in clinical practice.[1] Epidemiology and Global Burden: Pseudomonas aeruginosa accounts for approximately 7-8% of healthcare-associated infections (HAIs) and is a major cause of ICU-acquired infections (16-23%).It is a leading Gram-negative pathogen in nosocomial pneumonia, contributing to 10-20% of ventilator-associated pneumonia (VAP) cases, with mortality rates of 32-43%.It also causes ~10% of catheter-associated UTIs, 4-6% of surgical site infections, and ~4% of central line-associated bloodstream infections.Bloodstream infections carry high mortality (up to 59%), particularly in ICU and burn patients.Recent global surveillance reports indicate rising multidrug-resistant (MDR) and carbapenem-resistant strains, further increasing its clinical and economic burden.[2] Overview of Pseudomonas aeruginosaPseudomonas aeruginosa is a Gram-negative, aerobic, non-fermenting bacillus widely found in soil, water, and moist environments.It is an opportunistic pathogen known for causing healthcare-associated infections, particularly in immunocompromised patients.The organism exhibits intrinsic resistance to many antibiotics and has the ability to form biofilms, making infections difficult to treat.[3] Resistance MechanismsPseudomonas aeruginosa exhibits multidrug resistance through intrinsic, acquired, and adaptive mechanisms.Intrinsically, it has a low-permeability outer membrane (10-100× less permeable than E. coli) and loss of the OprD porin, leading to carbapenem resistance.It expresses multidrug efflux pumps (MexAB-OprM, MexXY-OprM) that expel β-lactams, fluoroquinolones, and aminoglycosides.Enzymatic inactivation includes inducible chromosomal AmpC β-lactamase, along with acquired ESBLs and carbapenemases (e.g., VIM, IMP, NDM), and aminoglycoside-modifying enzymes.Target-site mutations in gyrA/parC confer fluoroquinolone resistance, while 16S rRNA methylation reduces aminoglycoside binding.Additionally, biofilm formation promotes adaptive resistance through reduced drug penetration and persistence of dormant "persister" cells, contributing to chronic and recurrent infections.[4] Clinical Spectrum of Pseudomonas aeruginosa [5]Pseudomonas aeruginosa is an opportunistic pathogen that mainly causes infections in hospitalized, immunocompromised, or critically ill patients.It is particularly associated with device-related and healthcare-associated infections and may lead to severe, life-threatening disease.